Abstract Library

#4319 Everolimus combined with orlistat inhibits the development of neuroendocrine tumours by inhibiting the mTOR-PI3K-Akt signalling pathway

Introduction: Everolimus, an mTOR inhibitor, has demonstrated efficacy in NET treatment. Orlistat, used primarily for obesity management, inhibits fat absorption. This study investigates the potential synergistic effects of Everolimus combined with Orlistat on the development of NETs.

Conference:

Presenting Author:

Authors: Xu L, Tang Q, Ye M,

Keywords: Everolimus, orlistat, mTOR, PI3K/Akt, signalling pathway,

#3754 Real-world data regarding the obesity paradox in patients with gastroenteropancreatic (GEP) NENs in a single centre in the United Kingdom

Introduction: The obesity paradox is a hypothesis showing patients (pts) with obesity have a prolonged overall survival compared to the ones with a normal weight. This paradox is present in multiple types of gastrointestinal cancer. In one population-based study from the USA, this paradox is also present in pts with GEP-NENs. However real-world data for the UK are lacking.

Conference:

Presenting Author: Clement D

Authors: Clement D, Brown S, Dolly S, Kibriya N, Howard M,

Keywords: gep-nen, survival, bmi, obesity paradox,

#3750 The obesity paradox in patients with bronchial NENs in a single tertiary referral center in the United Kingdom

Introduction: In patients (pts) with lung cancer, there are multiple studies demonstrating obesity is significantly associated with improved overall survival (OS), this is known as the obesity paradox. It is unknown if this paradox exists in pts with bronchial NENs.

Conference:

Presenting Author: Clement D

Authors: Clement D, Richardson D, Shah N, Mulholland N, Sarker D,

Keywords: bronchial NEN, survival, obesity,

#3413 Visceral obesity at diagnosis is associated with well-differentiated neuroendocrine neoplasia lower progression free survival

Introduction: The association of well-differentiated gastroenteropancreatic neuroendocrine neoplasia (WD GEP-NEN) with metabolic syndrome (MetS), abdominal obesity, and fasting glucose abnormalities was recently described. Although the role of the intrinsic clinical, pathological, and molecular factors on GEP-NEN prognosis has been extensively studied, the association of adverse outcomes with obesity and metabolic risk factors was not identified so far.

Conference:

Presenting Author: Santos A

Authors: Santos A, Rodrigues J, Henrique R, Cardoso M, Monteiro M,

Keywords: gastroenteropancreatic neuroendocrine neoplasm, metabolic syndrome, visceral obesity, overall survival, progression free survival,

#3199 Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): A multicentre case-control study

Introduction: Pathogenesis and risk factors of sporadic GEP-NENs are not clear and still debated.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Feola T

Authors: Feola T, Puliani G, Sesti F, Centello R, Di Vito V,

Keywords: neuroendocrine neoplasm, risk factor, obesity, diabetes mellitus, low-HDL, gastroenteropancreatic, pancreas, ileum,